← FDA DRUG APPROVALS

FDA ANDA · ANDA215041

RIFABUTIN

Sponsor: NOVITIUM PHARMA

APPLICATION
ANDA215041
TYPE
ANDA
ORIGINAL APPROVAL
2021-12-17
LATEST ACTION
2025-07-10
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

RIFABUTINPrescription
RIFABUTIN 150MG · CAPSULE · ORAL

Approval history

2025-07-10Labeling · Supplement 15 · standardAP
2021-12-17UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →